Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
By E. Slow, Jeremy M. Van Raamsdonk, D. Rogers, S. Coleman, R. Graham, Yu Deng, R. Oh, N. Bissada, Sazzad M. Hossain, Yu-zhou Yang and 5 more. Human Molecular Genetics, 2003
843 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/9a0dc0ed110154a20916c4dd280d2da63dd70b10
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice (2008, background): “DOI:10.1523/JNEUROSCI.0857-08.2008 Copyright © 2008 Society for Neuroscience 0270-6474/08/286182-14$15.00/0 mice, culminate in selective cortical and striatal atrophy and neurodegeneration (Slow et al., 2003; Van Raamsdonk et al., 2005).”
- Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. (2006, methodology): “Significant brain atrophy and loss of striatal volume have previously been reported in HD53 mice by 9 months (Slow et al., 2003), in HD55 by 12 months, and in the lower-expressing HD54 line by 18 months (Graham et al., 2005).”